What is the main business of Europejski Instytut Biomedyczny?

The main business activity of Europejski Instytut Biomedyczny focuses on research and experimental development on biotechnology.

When was the company founded?

The company was registered in the Polish National Court Register (KRS) on December 20, 2021.

Where is the headquarters located?

The headquarters is located at: ul. Bartycka 63A, 00-716 Warszawa.

What is the share capital?

The share capital of the company is PLN 250,000 (approx. $67,531).

What period do the latest financial data cover?

The latest available financial statement covers the period from January 1, 2024 to December 31, 2024.

What was the revenue?

In 2024, the company generated total revenue of $2,838,651, representing an increase of 15.6% compared to 2023.

Yes, the company recorded a net profit of $1,033,921 in 2024, meaning the company increased its profit by 7.6%.

What is the largest operating cost?

The largest operating cost category falls under materials and energy. This category amounted to $582,908 in 2024, representing 38% of all operating expenses.

Europejski Instytut Biomedycznysp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status

Active

Registry date

2021-12-20

Share capital

250,000.00 PLN

Registered address

ul. Bartycka 63A/6, 00-716 Warszawa, Poland

Electronic delivery address

AE:PL-94770-16046-BERTS-11

Financials

Revenue history (in k)

Filing timeliness

Financial statements were filed on time, on average 34 days early.

2025filed
202414/07/2025
202328/05/2024
202224/05/2023

Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2025.

Results vs industry

Revenue

This companyUSD 3.37mMedianUSD 55.24kAverageUSD 2.71m

Net profit

This companyUSD 1.48mMedianUSD -1.27kAverageUSD -91.85k

Operating costs

This companyUSD 1.64mMedianUSD 65.85kAverageUSD 2.66m

Assets

This companyUSD 4.18mMedianUSD 133.19kAverageUSD 3.03m

Industry

Authorized Representatives

Damian Przemysław Matak – President of the Management Board

Manner of representation

For making declarations within the scope of the company's property and non-property rights and obligations and for signing on behalf of the company: in the case of a one-person management board, the President of the Management Board independently; in the case of a two- or three-member management board, two members of the management board or a member of the management board together with a commercial proxy.

Supervisory board

Klaudia Klarysa Brodaczewska – Supervisory Board Member

Konrad Gerard Brodaczewski – Supervisory Board Member

Wiesław Mieczysław Brodaczewski – Supervisory Board Member

Ownership

Owner	Share value	Stake
Konmex Limited	$67,531.06	100%

Beneficial owners

Person	Rights

Bank accounts

Registered as a VAT taxpayer on 2022-01-06.

ING Bank Śląski
39 1050 1025 1000 0090 8147 0933
ING Bank Śląski
06 1050 1025 1000 0024 8079 2635
ING Bank Śląski
83 1050 1025 1000 0090 8147 0917

Debt

No entries in the National Debtors Register (KRZ).

Public aid

No public aid cases recorded in the last 10 years.

Regulatory authorisations

Authority	Type	Status
BDO	BDO register entry	Active

Competitors

Name	Revenue	Website
FamicordtxS.A.	$1,365,068.41	famicordtx.com
Orphinic ScientificS.A.	$518,429.97	orphinic.com
Proper Medical Writingsp. z o.o.	$464,661.64	propermedicalwriting.com
Medicofarma BiotechS.A.	$314,882.33	medicofarmabiotech.pl
Explorna Therapeuticssp. z o.o.	$304,662.00	explorna.com
Frontline BiosciencesS.A.	$219,186.29	frontlinebiosciences.com
AI Corelabsp. z o.o.	$128,365.55	aicorelab.com
ModicaP.S.A.	$103,400.72	modica.bio
WPD Pharmaceuticalssp. z o.o.	$90,822.78	wpdpharmaceuticals.com
WPD PharmaceuticalsS.A.	$87,561.70	wpdpharmaceuticals.pl